SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications

January 9, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806277/0/en/SeaStar-Medical-Issued-U-S-Patent-with-Broad-Claims-Covering-Use-of-the-Selective-Cytopheretic-Device-for-Multiple-Clinical-Indications.html

DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the issuance of U.S. Patent No. 11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions and to process activated leukocytes and platelets. The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response.

Read more at globenewswire.com

Related news for (ICU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.